Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study

References

• National Cancer Institute SEER website [Internet]. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. SEER stat fact sheets: chronic lymphocytic leukemia (CLL). [Internet]; [cited 2017 Nov 27]. Available from: http://seer.cancer.gov/statfacts/html/clyl.html
   Google Scholar
• Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v78–v84.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Holtzer-Goor KM, Schaafsma MR, Joosten P, et al. Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study. Qual Life Res. 2015;24:2895–2906.
   PubMed Web of Science ®Google Scholar
• Molica S, Mirabelli R, Molica M, et al. Clinical relevance and treatment of nonautoimmune anemia in chronic lymphocytic leukemia. Cancer Manag Res. 2011;3:211–217.
   PubMedGoogle Scholar
• Stephens JM, Gramegna P, Laskin B, et al. Chronic lymphocytic leukemia: economic burden and quality of life: literature review. Am J Ther. 2005;12:460–466.
   PubMedGoogle Scholar
• Shanafelt TD, Bowen D, Venkat C, et al. Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol. 2007;139:255–264.
   PubMed Web of Science ®Google Scholar
• Johnsen AT, Tholstrup D, Petersen MA, et al. Health related quality of life in a nationally representative sample of haematological patients. Eur J Haematol. 2009;83:139–148.
   PubMed Web of Science ®Google Scholar
• Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol. 1998;25(3 Suppl 7):43–46.
   Web of Science ®Google Scholar
• Cella D, Lai JS, Chang CH, et al. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94:528–538.
   PubMed Web of Science ®Google Scholar
• Littlewood T, Mandelli F. The effects of anemia in hematologic malignancies: more than a symptom. Semin Oncol. 2002;29(3 Suppl 8):40–44.
   Web of Science ®Google Scholar
• Imbruvica [prescribing information]. Sunnyvale, CA, USA: Pharmacyclics LLC; 2016. [Internet]; Available from: https://www.imbruvica.com/prescribing-information
   Google Scholar
• Imbruvica [summary of product characteristics]. High Wycombe, UK: Janssen-Cilag Ltd; 2016. [Internet]; Available from: http://ec.europa.eu/health/documents/community-register/2014/20141021129815/anx_129815_en.pdf
   Google Scholar
• Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17:200–211.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29:3559–3566.
   PubMed Web of Science ®Google Scholar
• Strong LE. The past, present, and future of patient-reported outcomes in oncology. Am Soc Clin Oncol Educ Book. 2015;e616–e620. doi: 10.14694/EdBook_AM.2015.35.e616
   PubMedGoogle Scholar
• Basch E. Toward patient-centered drug development in oncology. N Engl J Med. 2013;369:397–400.
   PubMed Web of Science ®Google Scholar
• Basch E, Geoghegan C, Coons SJ, et al. Patient-reported outcomes in cancer drug development and US regulatory review: perspectives from industry, the Food and Drug Administration, and the patient. JAMA Oncol. 2015;1:375–379.
   PubMed Web of Science ®Google Scholar
• Fehnel S, DeMuro C, McLeod L, et al. US FDA patient-reported outcome guidance: great expectations and unintended consequences. Expert Rev Pharmacoecon Outcomes Res. 2013;13:441–446.
   PubMed Web of Science ®Google Scholar
• Schandelmaier S, Conen K, von EE, et al. Planning and reporting of quality-of-life outcomes in cancer trials. Ann Oncol. 2015;26:1966–1973.
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug Administration Web site [Internet]. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. [Internet]; [cited 2017 Nov 27]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf
   Google Scholar
• Kim ES, Bernstein D, Hilsenbeck SG, et al. Modernizing eligibility criteria for molecularly driven trials. J Clin Oncol. 2015;33:2815–2820.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376.
   PubMed Web of Science ®Google Scholar
• Knobel H, Loge JH, Brenne E, et al. The validity of EORTC QLQ-C30 fatigue scale in advanced cancer patients and cancer survivors. Palliat Med. 2003;17:664–672.
   PubMed Web of Science ®Google Scholar
• Holzner B, Bode RK, Hahn EA, et al. Equating EORTC QLQ-C30 and FACT-G scores and its use in oncological research. Eur J Cancer. 2006;42:3169–3177.
   PubMed Web of Science ®Google Scholar
• Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manag. 1997;13:63–74.
   PubMed Web of Science ®Google Scholar
• NICE Web site [Internet]. Falconer S, Lloyd A. Utility measurement study for patients with chronic lymphocytic leukaemia: interim report. [Internet]; [cited 2017 Nov 27]. Available from: https://www.nice.org.uk/guidance/ta174/documents/utility-measurement-study-for-patients-with-chronic-lymphocytic-leukaemia-interim-report2
   Google Scholar
• FACIT.org. Functional Assessment of Chronic Illness Therapy-Fatigue; a 13-item FACIT Fatigue Scale. 2017. April 24, 2017.
   Google Scholar
• Acaster S, Dickerhoof R, DeBusk K, et al. Qualitative and quantitative validation of the FACIT-fatigue scale in iron deficiency anemia. Health Qual Life Outcomes. 2015;13:60.
   PubMed Web of Science ®Google Scholar
• Cella D, Lai JS, Stone A. Self-reported fatigue: one dimension or more? Lessons from the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-F) questionnaire. Support Care Cancer. 2011;19:1441–1450.
   PubMed Web of Science ®Google Scholar
• Cella D, Yount S, Sorensen M, et al. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005;32:811–819.
   PubMed Web of Science ®Google Scholar
• Dapueto JJ, Abreu MC, Francolino C, et al. Psychometric assessment of the MSAS-SF and the FACIT-Fatigue Scale in Spanish-speaking patients with cancer in Uruguay. J Pain Symptom Manag. 2014;47:936–945.
   PubMed Web of Science ®Google Scholar
• Lai JS, Beaumont JL, Ogale S, et al. Validation of the functional assessment of chronic illness therapy-fatigue scale in patients with moderately to severely active systemic lupus erythematosus, participating in a clinical trial. J Rheumatol. 2011;38:672–679.
   PubMed Web of Science ®Google Scholar
• Cella D, Eton DT, Lai JS, et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manag. 2002;24:547–561.
   PubMed Web of Science ®Google Scholar
• Ediebah DE, Coens C, Zikos E, et al. Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial. Br J Cancer. 2014;110:2427–2433.
   PubMed Web of Science ®Google Scholar
• EORTC Quality of Life Web site [Internet]. EORTC - Chronic Lymphocytic Leukaemia (QLQ-CLL16). [Internet]; [cited 2017 Nov 27]. Available from: http://groups.eortc.be/qol/chronic-lymphocytic-leukaemia-qlq-cll16
   Google Scholar
• Devlin NJ, Krabbe PF. The development of new research methods for the valuation of EQ-5D-5L. Eur J Health Econ. 2013;14(Suppl 1):S1–S3.
   PubMed Web of Science ®Google Scholar
• EuroQoL Group Association Web site [Internet]. EuroQoL EQ-5D-5L Questionnaire. [Internet]; [cited 2017 Nov 27]. Available from: http://www.euroqol.org/about-eq-5d.html
   Google Scholar
• Movsas B, Hunt D, Watkins-Bruner D, et al. Can electronic web-based technology improve quality of life data collection? Analysis of Radiation Therapy Oncology Group 0828. Pract Radiat Oncol. 2014;4:187–191.
   PubMedGoogle Scholar
• Robak T, Warzocha K, Govind BK, et al. Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL. Leuk Lymphoma. 2017;58:1598–1606.
   PubMed Web of Science ®Google Scholar
• Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014;15:1090–1099.
   PubMed Web of Science ®Google Scholar
• Hess G, Rule S, Jurczak W, et al. Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus. Leuk Lymphoma. 2017;58:2824–2832.
   PubMed Web of Science ®Google Scholar